Microarrays & Multiplexing

CombiMatrix said that it had record prenatal microarray volume of 1,126 tests in the fourth quarter.

NanoString CEO Brad Gray said on a conference call that oncology was once a primary driver of new instrument placements. 

The firm said that it placed 38 XT-8 analyzers in Q4, bringing the total installed base of the instrument to 540 as of the end of 2014. 

The firm is also positioning MassArray as a complementary technology to NGS, and hopes to tap into the LDT and liquid biopsy arenas.

The molecular diagnostics firm offered more than 3.2 million shares of its stock at $2.80 per share as part of the offering. 

Multiplex detection of nucleic acids
Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms
Mutations in the LNK gene in patients with myeloproliferative neoplasms and other hematolymphoid malignancies
Nucleic-acid-responsive gel, method for producing same, and use of same
Methods for detection and typing of nucleic acids
Integrated sensor arrays for biological and chemical analysis